NDAINJECTIONINJECTABLE
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CARDIZEM (diltiazem hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology the therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for hypertension, chronic stable angina, angina due to coronary artery spasm. First approved in 1991.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM (diltiazem hydrochloride) is a non-dihydropyridine calcium channel blocker administered via injection for acute cardiovascular indications. It treats hypertension, chronic stable angina, and angina due to coronary artery spasm by inhibiting cellular calcium influx, reducing myocardial oxygen demand and peripheral vascular resistance. The drug's mechanism enables coronary vasodilation and reduced heart rate, improving exercise tolerance in ischemic heart disease patients.
$0.224MPart D
LOE ApproachingDeclining
Minimal commercial opportunity; approaching loss of exclusivity with negligible team size and declining Part D utilization signals defensive portfolio positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect…
Worked on CARDIZEM at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.